Direct To Consumer User Fee Program Formally Ends
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA notes DTC ads will be pre-reviewed “as resources permit.”
You may also be interested in...
Priority Review Vouchers One Step Closer, But Congress Must Act Again
FDA will not be able to review applications covered by a priority review voucher until it receives Congressional authorization to collect a special user fee to support the program, the agency says in a draft guidance on the new incentive for pharmaceutical companies
Priority Review Vouchers One Step Closer, But Congress Must Act Again
FDA will not be able to review applications covered by a priority review voucher until it receives Congressional authorization to collect a special user fee to support the program, the agency says in a draft guidance on the new incentive for pharmaceutical companies
Priority Review Vouchers One Step Closer, But Congress Must Act Again
FDA guidance on incentive for neglected tropical disease research clarifies some key questions—but also stresses need for appropriation authority to make program work.